132 related articles for article (PubMed ID: 11747276)
21. ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.
Braun S; Schlimok G; Heumos I; Schaller G; Riethdorf L; Riethmüller G; Pantel K
Cancer Res; 2001 Mar; 61(5):1890-5. PubMed ID: 11280743
[TBL] [Abstract][Full Text] [Related]
22. Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.
Diel IJ; Kaufmann M; Costa SD; Holle R; von Minckwitz G; Solomayer EF; Kaul S; Bastert G
J Natl Cancer Inst; 1996 Nov; 88(22):1652-8. PubMed ID: 8931609
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapy.
Braun S; Cevatli BS; Assemi C; Janni W; Kentenich CR; Schindlbeck C; Rjosk D; Hepp F
J Clin Oncol; 2001 Mar; 19(5):1468-75. PubMed ID: 11230493
[TBL] [Abstract][Full Text] [Related]
24. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
25. Bone marrow micrometastases and adjuvant treatment of breast cancer.
Yu JJ; Brennan M; Christos P; Osborne MP; Hoda S; Simmons RM
Breast J; 2004; 10(3):181-5. PubMed ID: 15125741
[TBL] [Abstract][Full Text] [Related]
26. Clinical relevance of occult metastatic cells in the bone marrow of patients with different stages of breast cancer.
Janni W; Rjosk D; Braun S
Clin Breast Cancer; 2000 Oct; 1(3):217-25. PubMed ID: 11899646
[TBL] [Abstract][Full Text] [Related]
27. Bone-marrow micrometastases in patients with brain metastases from epithelial cell tumours.
Maguire D; O'Sullivan GC; McNamara B; Collins JK; Shanahan F
QJM; 2000 Sep; 93(9):611-5. PubMed ID: 10984556
[TBL] [Abstract][Full Text] [Related]
28. [Technical aspects of immunocytochemical detection of disseminated tumor cells in bone marrow].
Braun S
Acta Med Austriaca Suppl; 2002; 59():14-7. PubMed ID: 12506755
[TBL] [Abstract][Full Text] [Related]
29. Micrometastases in bone marrow: prognostic indicators for pancreatic cancer.
Roder JD; Thorban S; Pantel K; Siewert JR
World J Surg; 1999 Sep; 23(9):888-91. PubMed ID: 10449815
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of proliferative potential of occult metastatic cells in bone marrow of patients with breast cancer.
Pierga JY; Bonneton C; Magdelénat H; Vincent-Salomon A; Nos C; Pouillart P; Thiery JP
Br J Cancer; 2003 Aug; 89(3):539-45. PubMed ID: 12888827
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of bone marrow micrometastasis detected by nested rt-PCR for keratin-19 in breast cancer patients.
Jung YS; Lee KJ; Kim HJ; Yim HE; Park JS; Soh EY; Kim MW; Park HB
Jpn J Clin Oncol; 2003 Apr; 33(4):167-72. PubMed ID: 12810830
[TBL] [Abstract][Full Text] [Related]
32. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes.
Crump M; Goss PE; Prince M; Girouard C
J Clin Oncol; 1996 Jan; 14(1):66-9. PubMed ID: 8558222
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation.
Fields KK; Elfenbein GJ; Trudeau WL; Perkins JB; Janssen WE; Moscinski LC
J Clin Oncol; 1996 Jun; 14(6):1868-76. PubMed ID: 8656255
[TBL] [Abstract][Full Text] [Related]
34. Molecular determinants of occult metastatic tumor cells in bone marrow.
Pantel K; Braun S
Clin Breast Cancer; 2001 Oct; 2(3):222-8. PubMed ID: 11899416
[TBL] [Abstract][Full Text] [Related]
35. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy.
Becker S; Becker-Pergola G; Wallwiener D; Solomayer EF; Fehm T
Breast Cancer Res Treat; 2006 May; 97(1):91-6. PubMed ID: 16319975
[TBL] [Abstract][Full Text] [Related]
36. Minimal residual disease in breast cancer.
Kvalheim G; Naume B; Nesland JM
Cancer Metastasis Rev; 1999; 18(1):101-8. PubMed ID: 10505549
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease.
Kufer P; Zippelius A; Lutterbüse R; Mecklenburg I; Enzmann T; Montag A; Weckermann D; Passlick B; Prang N; Reichardt P; Dugas M; Köllermann MW; Pantel K; Riethmüller G
Cancer Res; 2002 Jan; 62(1):251-61. PubMed ID: 11782385
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA.
Vannucchi AM; Bosi A; Glinz S; Pacini P; Linari S; Saccardi R; Alterini R; Rigacci L; Guidi S; Lombardini L; Longo G; Mariani MP; Rossi-Ferrini P
Br J Haematol; 1998 Dec; 103(3):610-7. PubMed ID: 9858208
[TBL] [Abstract][Full Text] [Related]
39. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer.
Klein CA; Blankenstein TJ; Schmidt-Kittler O; Petronio M; Polzer B; Stoecklein NH; Riethmüller G
Lancet; 2002 Aug; 360(9334):683-9. PubMed ID: 12241875
[TBL] [Abstract][Full Text] [Related]
40. Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast carcinoma cell contamination.
Ballestrero A; Coviello DA; Garuti A; Nencioni A; Famà A; Rocco I; Bertorelli R; Ferrando F; Gonella R; Patrone F
Cancer; 2001 Oct; 92(8):2030-5. PubMed ID: 11596016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
